Literature DB >> 6131657

Alprazolam kinetics in the elderly. Relation to antipyrine disposition.

D J Greenblatt, M Divoll, D R Abernethy, L J Moschitto, R B Smith, R I Shader.   

Abstract

The pharmacokinetics of alprazolam, a triazolobenzodiazepine anxiolytic-antidepressant, were assessed in 32 healthy men and women aged 21 to 78 years after a single 1.0-mg oral dose. Peak alprazolam levels averaged 20.4 ng/mL and were reached a mean of 1.25 hours after dosage. Mean elimination half-life did not differ significantly between elderly and young women, nor did total metabolic clearance. However, half-life was significantly prolonged, and total clearance significantly reduced, in elderly v young men. Antipyrine oxidizing capacity was also evaluated, and half-life for the two drugs was highly correlated, as were their metabolic clearances. Thus, old age is associated with impaired capacity to oxidize alprazolam, but this effect is far more apparent in men than in women. A test of antipyrine half-life and clearance may help identify slow or rapid metabolizers of alprazolam.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131657     DOI: 10.1001/archpsyc.1983.01790030057007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  27 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.

Authors:  J M Scavone; D J Greenblatt; J E Goddard; H Friedman; J S Harmatz; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 5.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

6.  Close correlation of acetaminophen clearance with that of conjugated benzodiazepines but not oxidized benzodiazepines.

Authors:  D J Greenblatt; D R Abernethy; M Divoll; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys.

Authors:  H Friedman; D E Redmond; D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 8.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 9.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

10.  The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R B Smith; R I Shader
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.